Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
   PubMed Web of Science ®Google Scholar
• Craig AJ, Von Felden J, Garcia-Lezana T, et al. Tumour evolution in hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2020;17:139–152.
   Google Scholar
• Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17:457–474.
   PubMed Web of Science ®Google Scholar
• Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov. 2013;3:1228–1237.
   PubMed Web of Science ®Google Scholar
• Gong D, Yang F, Li F, et al. Crystal structure and functional characterization of the human RBM25 PWI domain and its flanking basic region. Biochem J. 2013;450:85–94.
   PubMed Web of Science ®Google Scholar
• Kanno T, Lin WD, Fu JL, et al. Screen for Pre-mRNA splicing mutants of arabidopsis thaliana identifies putative U1 snRNP components RBM25 and PRP39a. Genetics. 2017;207:1347–1359.
   PubMed Web of Science ®Google Scholar
• Zhou A, Ou AC, Cho A, et al. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5’ splice site selection. Mol Cell Biol. 2008;28:5924–5936.
   PubMed Web of Science ®Google Scholar
• Yang Z, Qu CB, Zhang Y, et al. Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene. 2019;38:2516–2532.
   PubMed Web of Science ®Google Scholar
• Mohammad DK, Ali RH, Turunen JJ, et al. B cell receptor activation predominantly regulates AKT-mTORC1/2 substrates functionally related to RNA processing. PloS One. 2016;11:e0160255.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai Q, Shu XO, et al. Whole-exome sequencing identifies novel somatic mutations in chinese breast cancer patients. J Mol Genet Med. 2015;9:9.
   Google Scholar
• Ge Y, Schuster MB, Pundhir S, et al. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia. Nat Commun. 2019;10:172.
   PubMed Web of Science ®Google Scholar
• Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27:233–244.
   PubMed Web of Science ®Google Scholar
• Gillinder KR, Tuckey H, Bell CC, et al. Direct targets of pSTAT5 signalling in erythropoiesis. PloS One. 2017;12:e0180922.
   PubMed Web of Science ®Google Scholar
• Wang H, Song X, Wang Y, et al. CircCNTNAP3-TP53-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma. Cell Death Dis. 2020;11:1010.
   PubMed Web of Science ®Google Scholar
• Atala A. Re: dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. J Urol. 2020;203:256–257.
   Google Scholar
• Yuan JH, Liu XN, Wang TT, et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. Nat Cell Biol. 2017;19:820–832.
   PubMed Web of Science ®Google Scholar
• Lu Y, Xu W, Ji J, et al. Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. Hepatology. 2015;62:1122–1131.
   PubMed Web of Science ®Google Scholar
• Guo AJ, Wang FJ, Ji Q, et al. Proteome analyses reveal S100A11, S100P, and RBM25 are tumor biomarkers in colorectal cancer. Proteomics Clin Appl. 2021;15:e2000056.
   PubMed Web of Science ®Google Scholar
• Huang WT, Liu AG, Cai KT, et al. Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma. Am J Transl Res. 2019;11:7538–7554.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wen DY, Zhang R, et al. A preliminary investigation of PVT1 on the effect and mechanisms of hepatocellular carcinoma: evidence from clinical data, a meta-analysis of 840 cases, and in vivo validation. Cell Physiol Biochem. 2018;47:2216–2232.
   PubMedGoogle Scholar
• Shen A, Liu L, Chen H, et al. Cell division cycle associated 5 promotes colorectal cancer progression by activating the ERK signaling pathway. Oncogenesis. 2019;8:19.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Koinuma J, Ueda K, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res. 2010;70:5337–5347.
   PubMed Web of Science ®Google Scholar
• Hou S, Chen X, Li M, et al. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma. Aging (Albany NY). 2020;12:14542–14555.
   PubMedGoogle Scholar
• Zhang X, Yan Z, Wang L, et al. STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis. J Cell Biochem. 2020.
   Web of Science ®Google Scholar
• Tian Y, Wu J, Chagas C, et al. CDCA5 overexpression is an indicator of poor prognosis in patients with hepatocellular carcinoma (HCC). BMC Cancer. 2018;18:1187.
   PubMed Web of Science ®Google Scholar
• Chen H, Chen J, Zhao L, et al. CDCA5, transcribed by E2F1, promotes oncogenesis by enhancing cell proliferation and inhibiting apoptosis via the AKT pathway in hepatocellular carcinoma. J Cancer. 2019;10:1846–1854.
   PubMed Web of Science ®Google Scholar
• Sun M, Veschi V, Bagchi S, et al. Targeting the chromosomal passenger complex subunit INCENP induces polyploidization, apoptosis, and senescence in neuroblastoma. Cancer Res. 2019;79:4937–4950.
   PubMed Web of Science ®Google Scholar
• Zhao L, Jiang L, He L, et al. Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. J Cell Physiol. 2019;234:6350–6360.
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Lee SH. The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis. Front Cell Dev Biol. 2015;3:14.
   PubMed Web of Science ®Google Scholar
• Soriano A, Masanas M, Boloix A, et al. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma. Cell Mol Life Sci. 2019;76:2231–2243.
   PubMed Web of Science ®Google Scholar
• Kabisch M, Lorenzo Bermejo J, Dunnebier T, et al. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis. 2015;36:256–271.
   PubMed Web of Science ®Google Scholar